METHOD FOR PREDICTION OF PROGRESSION OF DIABETIC RETINOPATHY AND DIABETIC MACULAR OEDEMA Russian patent published in 2014 - IPC A61B3/06 A61B3/00 G01N33/49 

FIELD: medicine.

SUBSTANCE: blood plasma glycated haemoglobin and lachrymal vascular endothelial growth factor VEGF are measured by enzyme-linked immunosorbent assay. There are derived a criterion R1 characterising an intensity of the macular oedema; a criterion R2 characterising a degree of sensitivity threshold shift; a criterion R3 reflecting a character of relations of retinal morphological structures describing an intensity of the oedema as shown by the criterion R1, and a degree of diabetes mellitus compensation; criterion R4 reflecting the relation of the retinal morphological structures as shown by the criterion R1 and VEGF. The correlated relations of the criteria R1-R4 provide a basis to calculate Rcom that is an integral criterion of progression reflecting the developmental character and a risk of progression of diabetic retinopathy (DRP) and diabetic macular oedema (DMO). If Rcom≤0.07, a neuroproliferative stage is diagnosed, and a low risk of progression of DRP and DMO is predicted. If 0.07<Rcom<0.18, a pre-proliferative stage is diagnosed, and a high risk of progression of DRP and DMO is predicted. The values within 0.18≤Rcom≤1.0 enables diagnosing a proliferative stage, and a high risk of progression of DRP and DMO with an unfavourable outcome for vision is predicted.

EFFECT: method provides an objective quantitative assessment of a risk of development and progression of DRP with DMO, presenting an entire aspect of the disease, including morphological and functional changes of the central retina determining a visual acuity, an effect of VEGF on DRP and DMO pathogenesis, a degree of diabetes mellitus compensation.

11 dwg, 2 ex